Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) has been given a consensus recommendation of “Buy” by the six ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $26.33.
A number of equities research analysts have commented on CRBP shares. Noble Financial upped their price target on Corbus Pharmaceuticals from $16.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, November 8th. BidaskClub lowered Corbus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, December 20th. Cantor Fitzgerald set a $28.00 price target on Corbus Pharmaceuticals and gave the company an “overweight” rating in a research report on Thursday, December 14th. Finally, Raymond James Financial started coverage on Corbus Pharmaceuticals in a research report on Friday. They issued an “outperform” rating and a $24.00 price target on the stock.
In other Corbus Pharmaceuticals news, Director David P. Hochman bought 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The shares were bought at an average price of $6.90 per share, for a total transaction of $34,500.00. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, Director David P. Hochman bought 10,000 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The shares were acquired at an average price of $7.08 per share, for a total transaction of $70,800.00. Following the transaction, the director now owns 459,500 shares in the company, valued at $3,253,260. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 25,336 shares of company stock worth $175,632. 11.90% of the stock is owned by corporate insiders.
Corbus Pharmaceuticals (NASDAQ CRBP) traded down $0.25 during midday trading on Friday, hitting $7.95. The company’s stock had a trading volume of 483,900 shares, compared to its average volume of 921,800. Corbus Pharmaceuticals has a 1 year low of $5.30 and a 1 year high of $10.50. The company has a market cap of $455.31, a price-to-earnings ratio of -12.82 and a beta of 174.68.
Corbus Pharmaceuticals (NASDAQ:CRBP) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. Corbus Pharmaceuticals had a negative return on equity of 96.02% and a negative net margin of 1,040.41%. The firm had revenue of $0.80 million for the quarter. equities analysts expect that Corbus Pharmaceuticals will post -0.6 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2018/01/19/corbus-pharmaceuticals-holdings-inc-crbp-given-consensus-recommendation-of-buy-by-brokerages.html.
About Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.